Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer
文献类型：期刊论文
| 作者 | Wei, Dan1,2; Wang, Hanlin2,3,4; Zeng, Qinghe1,2; Wang, Wenjing1,2; Hao, Bingbing4; Feng, Xule1; Wang, Peipei4 ; Song, Ning2,4; Kan, Weijuan4; Huang, Guifang5
|
| 刊名 | JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2021-10-14 |
| 卷号 | 64期号:19页码:14822-14847 |
| ISSN号 | 0022-2623 |
| DOI | 10.1021/acs.jmedchem.1c01350 |
| 通讯作者 | Huang, Ruimin(rmhuang@simm.ac.cn) ; Li, Jia(jli@simm.ac.cn) ; Chen, Xiao-Hua(xhchen@simm.ac.cn) |
| 英文摘要 | Triple-negative breast cancer (TNBC) is highly aggressive with very limited treatment options due to the lack of efficient targeted therapies and thus still remains clinically challenging. Targeting transcription-associated cyclin-dependent kinases to remodel transcriptional regulation shows great promise in cancer therapy. Herein, we report the synthesis, optimization, and evaluation of new series of heterobifunctional molecules as highly selective and efficacious CDK9 degraders, enabling potent inhibition of TNBC cell growth and rapidly targeted degradation of CDK9. Moreover, the most potent CDK9 degrader (compound 45) induces cell apoptosis in vitro and inhibits tumor growth in the MDA-MB-231 TNBC model. Furthermore, the RNA-seq, immunohistochemistry assays demonstrate that the CDK9 degrader downregulates the downstream targets, such as MYC, at the transcriptional level, resulting apoptosis in TNBC cells. Our work establishes that 45 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation, which represents an effective strategy and great potential as a new targeted therapy for TNBC. |
| WOS关键词 | BET BROMODOMAIN INHIBITORS ; CYCLIN-DEPENDENT KINASES ; SYNTHETIC LETHAL ; RESISTANCE ; PROTACS ; UBIQUITINATION ; DEGRADATION ; PROTEOLYSIS ; ADDICTION ; COMPLEX |
| 资助项目 | National Science Foundation of China (NSFC)[92053106] ; National Science Foundation of China (NSFC)[22177120] ; National Science Foundation of China (NSFC)[91859106] ; National Science Foundation of China (NSFC)[81821005] ; Science and Technology Commission of Shanghai Municipality, China[18431907100] ; Science and Technology Commission of Shanghai Municipality, China[20S11901400] ; Science and Technology Commission of Shanghai Municipality, China[16431902200] ; Science and Technology Commission of Shanghai Municipality, China[21S11907500] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000709633100047 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/298686]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Huang, Ruimin; Li, Jia; Chen, Xiao-Hua |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Fudan Univ, Coll Pharm, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China 6.Chinese Acad Sci, Inst Drug Discovery & Dev, Zhongshan Inst Drug Discovery, Zhongshan 528400, Guangdong, Peoples R China 7.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wei, Dan,Wang, Hanlin,Zeng, Qinghe,et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer[J]. JOURNAL OF MEDICINAL CHEMISTRY,2021,64(19):14822-14847. |
| APA | Wei, Dan.,Wang, Hanlin.,Zeng, Qinghe.,Wang, Wenjing.,Hao, Bingbing.,...&Chen, Xiao-Hua.(2021).Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.JOURNAL OF MEDICINAL CHEMISTRY,64(19),14822-14847. |
| MLA | Wei, Dan,et al."Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer".JOURNAL OF MEDICINAL CHEMISTRY 64.19(2021):14822-14847. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。